ProPhase Labs (NASDAQ:PRPH – Get Free Report) is expected to release its earnings data before the market opens on Thursday, March 27th. Analysts expect ProPhase Labs to post earnings of ($0.24) per share and revenue of $3.77 million for the quarter.
ProPhase Labs Trading Up 2.0 %
NASDAQ PRPH opened at $0.40 on Thursday. ProPhase Labs has a 12 month low of $0.22 and a 12 month high of $7.48. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.47 and a quick ratio of 1.33. The company has a market capitalization of $9.52 million, a price-to-earnings ratio of -0.32 and a beta of -0.53. The company’s fifty day moving average price is $0.44 and its two-hundred day moving average price is $1.19.
Analysts Set New Price Targets
Separately, StockNews.com assumed coverage on shares of ProPhase Labs in a report on Tuesday, February 25th. They set a “sell” rating on the stock.
About ProPhase Labs
ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
Featured Articles
- Five stocks we like better than ProPhase Labs
- When to Sell a Stock for Profit or Loss
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- How is Compound Interest Calculated?
- Alphabet’s Officially In A Bear Market—Time To Buy?
- Health Care Stocks Explained: Why You Might Want to Invest
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.
